{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:23:00Z","timestamp":1792671780468,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cognitive impairment is a core characteristic of schizophrenia, but its underlying neural mechanisms remain poorly understood. Reduced brain-derived neurotrophic factor (BDNF), a protein critical for neural plasticity and synaptic signaling, is one of the few molecules consistently associated with cognitive deficits in schizophrenia although the etiological pathway leading to BDNF reduction in schizophrenia is unclear. We examined microRNA-195 (miR-195), a known modulator of BDNF protein expression, as a potential mechanistic component. One-hundred and eighteen first-episode patients with schizophrenia either antipsychotic medication-na\u00efve or within two weeks of antipsychotic medication exposure and forty-seven age- and sex-matched healthy controls were enrolled. MiR-195 and BDNF mRNA and BDNF protein levels in peripheral blood were tested. Cognitive function was assessed using the MATRICS Consensus Cognitive Battery (MCCB). MiR-195 was significantly higher (<jats:italic>p<\/jats:italic>\u2009=\u20090.01) whereas BDNF mRNA (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and protein (<jats:italic>p<\/jats:italic>\u2009=\u20090.016) levels were significantly lower in patients compared with controls. Higher miR-195 expression was significantly correlated to lower BDNF protein levels in patients (partial <jats:italic>r<\/jats:italic>\u2009=\u2009\u22120.28, <jats:italic>p<\/jats:italic>\u2009=\u20090.003) and lower BDNF protein levels were significantly associated with poorer overall cognitive performance by MCCB and also in speed of processing, working memory, and attention\/vigilance domains composite score (<jats:italic>p<\/jats:italic>\u2009=\u20090.002\u20130.004). The subgroup of patients with high miR-195 and low BDNF protein showed the lowest level of cognitive functions, and miR-195 showed significant mediation effects on cognitive functions through BDNF protein. Elevated miR-195 may play a role in regulating BDNF protein expression thereby influencing cognitive impairments in schizophrenia, suggesting that development of cognition enhancing treatment for schizophrenia may consider a micro-RNA based strategy.<\/jats:p>","DOI":"10.1038\/s41398-021-01240-x","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:12:44Z","timestamp":1612829564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["The microRNA-195 - BDNF pathway and cognitive deficits in schizophrenia patients with minimal antipsychotic medication exposure"],"prefix":"10.1038","volume":"11","author":[{"given":"Shujuan","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junchao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baopeng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuping","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiren","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangwu","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Chiappelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kochunov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fude","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9393-1212","authenticated-orcid":false,"given":"Chiang-Shan R.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0222-7076","authenticated-orcid":false,"given":"Li","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3522-3912","authenticated-orcid":false,"given":"Yunlong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Elliot Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,8]]},"reference":[{"key":"1240_CR1","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/jamapsychiatry.2013.155","volume":"70","author":"RS Kahn","year":"2013","unstructured":"Kahn, R. S. & Keefe, R. S. Schizophrenia is a cognitive illness: time for a change in focus. JAMA Psychiatry 70, 1107\u20131112 (2013).","journal-title":"JAMA Psychiatry"},{"key":"1240_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","volume":"136","author":"DP Bartel","year":"2009","unstructured":"Bartel, D. P. MicroRNAs: target recognition and regulatory functions. Cell 136, 215\u2013233 (2009).","journal-title":"Cell"},{"key":"1240_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1001214","volume":"9","author":"M Somel","year":"2011","unstructured":"Somel, M. et al. MicroRNA-driven developmental remodeling in the brain distinguishes humans from other primates. PLoS Biol. 9, e1001214 (2011).","journal-title":"PLoS Biol."},{"key":"1240_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2015.11.021","volume":"104","author":"BT Woldemichael","year":"2016","unstructured":"Woldemichael, B. T. & Mansuy, I. M. Micro-RNAs in cognition and cognitive disorders: Potential for novel biomarkers and therapeutics. Biochem. Pharmacol. 104, 1\u20137 (2016).","journal-title":"Biochem. Pharmacol."},{"key":"1240_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3389\/fncel.2014.00015","volume":"8","author":"MJ Kye","year":"2014","unstructured":"Kye, M. J. & Goncalves Ido, C. The role of miRNA in motor neuron disease. Front. Cell. Neurosci. 8, 15 (2014).","journal-title":"Front. Cell. Neurosci."},{"key":"1240_CR6","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1007\/s00018-015-1922-2","volume":"72","author":"F Afonso-Grunz","year":"2015","unstructured":"Afonso-Grunz, F. & Muller, S. Principles of miRNA-mRNA interactions: beyond sequence complementarity. Cell. Mol. Life Sci. 72, 3127\u20133141 (2015).","journal-title":"Cell. Mol. Life Sci."},{"key":"1240_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-016-0893-x","volume":"14","author":"LF Gulyaeva","year":"2016","unstructured":"Gulyaeva, L. F. & Kushlinskiy, N. E. Regulatory mechanisms of microRNA expression. J. Transl. Med. 14, 143 (2016).","journal-title":"J. Transl. Med."},{"key":"1240_CR8","doi-asserted-by":"publisher","first-page":"6457","DOI":"10.1007\/s13277-015-4540-6","volume":"37","author":"Z Li","year":"2016","unstructured":"Li, Z., Wang, H., Wang, Z. & Cai, H. MiR-195 inhibits the proliferation of human cervical cancer cells by directly targeting cyclin D1. Tumour Biol. 37, 6457\u20136463 (2016).","journal-title":"Tumour Biol."},{"key":"1240_CR9","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.jocn.2014.08.018","volume":"22","author":"XY Sun","year":"2015","unstructured":"Sun, X. Y. et al. Aberrant microRNA expression in peripheral plasma and mononuclear cells as specific blood-based biomarkers in schizophrenia patients. J. Clin. Neurosci. 22, 570\u2013574 (2015).","journal-title":"J. Clin. Neurosci."},{"key":"1240_CR10","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1093\/hmg\/ddn201","volume":"17","author":"N Mellios","year":"2008","unstructured":"Mellios, N., Huang, H. S., Grigorenko, A., Rogaev, E. & Akbarian, S. A set of differentially expressed miRNAs, including miR-30a-5p, act as post-transcriptional inhibitors of BDNF in prefrontal cortex. Hum. Mol. Genet. 17, 3030\u20133042 (2008).","journal-title":"Hum. Mol. Genet."},{"key":"1240_CR11","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.biopsych.2008.11.019","volume":"65","author":"N Mellios","year":"2009","unstructured":"Mellios, N. et al. Molecular determinants of dysregulated GABAergic gene expression in the prefrontal cortex of subjects with schizophrenia. Biol. Psychiatry 65, 1006\u20131014 (2009).","journal-title":"Biol. Psychiatry"},{"key":"1240_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/1752-0509-4-10","volume":"4","author":"AY Guo","year":"2010","unstructured":"Guo, A. Y., Sun, J., Jia, P. & Zhao, Z. A novel microRNA and transcription factor mediated regulatory network in schizophrenia. BMC Syst. Biol. 4, 10 (2010).","journal-title":"BMC Syst. Biol."},{"key":"1240_CR13","doi-asserted-by":"publisher","first-page":"8163","DOI":"10.1093\/nar\/gkr532","volume":"39","author":"PT Nelson","year":"2011","unstructured":"Nelson, P. T. et al. Specific sequence determinants of miR-15\/107 microRNA gene group targets. Nucleic Acids Res. 39, 8163\u20138172 (2011).","journal-title":"Nucleic Acids Res."},{"key":"1240_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/978-3-642-45106-5_9","volume":"220","author":"B Lu","year":"2014","unstructured":"Lu, B., Nagappan, G. & Lu, Y. BDNF and synaptic plasticity, cognitive function, and dysfunction. Handb. Exp. Pharmacol. 220, 223\u2013250 (2014).","journal-title":"Handb. Exp. Pharmacol."},{"key":"1240_CR15","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.psychres.2019.01.051","volume":"273","author":"Y Yang","year":"2019","unstructured":"Yang, Y. et al. Brain-derived neurotrophic factor is associated with cognitive impairments in first-episode and chronic schizophrenia. Psychiatry Res. 273, 528\u2013536 (2019).","journal-title":"Psychiatry Res."},{"key":"1240_CR16","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1080\/15622975.2016.1212172","volume":"18","author":"H Hori","year":"2017","unstructured":"Hori, H. et al. Relationships between serum brain-derived neurotrophic factor, plasma catecholamine metabolites, cytokines, cognitive function and clinical symptoms in Japanese patients with chronic schizophrenia treated with atypical antipsychotic monotherapy. World J. Biol. Psychiatry 18, 401\u2013408 (2017).","journal-title":"World J. Biol. Psychiatry"},{"key":"1240_CR17","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00213-014-3660-9","volume":"232","author":"JQ Wu","year":"2015","unstructured":"Wu, J. Q. et al. Altered BDNF is correlated to cognition impairment in schizophrenia patients with tardive dyskinesia. Psychopharmacology 232, 223\u2013232 (2015).","journal-title":"Psychopharmacology"},{"key":"1240_CR18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.neulet.2008.05.022","volume":"439","author":"HJ Reis","year":"2008","unstructured":"Reis, H. J. et al. Increased serum levels of brain-derived neurotrophic factor in chronic institutionalized patients with schizophrenia. Neurosci. Lett. 439, 157\u2013159 (2008).","journal-title":"Neurosci. Lett."},{"key":"1240_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.neulet.2003.08.004","volume":"351","author":"E Shimizu","year":"2003","unstructured":"Shimizu, E. et al. Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls. Neurosci. Lett. 351, 111\u2013114 (2003).","journal-title":"Neurosci. Lett."},{"key":"1240_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-15751-5","volume":"7","author":"S Liu","year":"2017","unstructured":"Liu, S. et al. Diagnostic value of blood-derived microRNAs for schizophrenia: results of a meta-analysis and validation. Sci. Rep. 7, 15328 (2017).","journal-title":"Sci. Rep."},{"key":"1240_CR21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jpsychires.2011.09.010","volume":"46","author":"W Shi","year":"2012","unstructured":"Shi, W. et al. Aberrant expression of serum miRNAs in schizophrenia. J. Psychiatr. Res. 46, 198\u2013204 (2012).","journal-title":"J. Psychiatr. Res."},{"key":"1240_CR22","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jpsychires.2014.03.008","volume":"54","author":"HT Song","year":"2014","unstructured":"Song, H. T. et al. A preliminary analysis of association between the down-regulation of microRNA-181b expression and symptomatology improvement in schizophrenia patients before and after antipsychotic treatment. J. Psychiatr. Res. 54, 134\u2013140 (2014).","journal-title":"J. Psychiatr. Res."},{"key":"1240_CR23","doi-asserted-by":"publisher","first-page":"104748","DOI":"10.1016\/j.psyneuen.2020.104748","volume":"119","author":"X Huang","year":"2020","unstructured":"Huang, X. et al. Sex difference in cognitive impairment in drug-free schizophrenia: association with miR-195 levels. Psychoneuroendocrinology 119, 104748 (2020).","journal-title":"Psychoneuroendocrinology"},{"key":"1240_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.schres.2015.09.003","volume":"169","author":"C Shi","year":"2015","unstructured":"Shi, C. et al. The MATRICS Consensus Cognitive Battery (MCCB): co-norming and standardization in China. Schizophr. Res. 169, 109\u2013115 (2015).","journal-title":"Schizophr. Res."},{"key":"1240_CR25","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1176\/appi.ajp.2007.07010042","volume":"165","author":"KH Nuechterlein","year":"2008","unstructured":"Nuechterlein, K. H. et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am. J. Psychiatry 165, 203\u2013213 (2008).","journal-title":"Am. J. Psychiatry"},{"key":"1240_CR26","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1176\/appi.ajp.2007.07010043","volume":"165","author":"RS Kern","year":"2008","unstructured":"Kern, R. S. et al. The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am. J. Psychiatry 165, 214\u2013220 (2008).","journal-title":"Am. J. Psychiatry"},{"key":"1240_CR27","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1037\/1082-989X.7.4.422","volume":"7","author":"PE Shrout","year":"2002","unstructured":"Shrout, P. E. & Bolger, N. Mediation in experimental and nonexperimental studies: new procedures and recommendations. Psychol. Methods 7, 422\u2013445 (2002).","journal-title":"Psychol. Methods"},{"key":"1240_CR28","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/jbt.20396","volume":"25","author":"JF He","year":"2011","unstructured":"He, J. F., Luo, Y. M., Wan, X. H. & Jiang, D. Biogenesis of MiRNA-195 and its role in biogenesis, the cell cycle, and apoptosis. J. Biochem. Mol. Toxicol. 25, 404\u2013408 (2011).","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"1240_CR29","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.schres.2018.06.017","volume":"201","author":"RJ Jirsaraie","year":"2018","unstructured":"Jirsaraie, R. J., Sheffield, J. M. & Barch, D. M. Neural correlates of global and specific cognitive deficits in schizophrenia. Schizophr. Res. 201, 237\u2013242 (2018).","journal-title":"Schizophr. Res."},{"key":"1240_CR30","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.nicl.2017.08.008","volume":"16","author":"K Ohi","year":"2017","unstructured":"Ohi, K. et al. Cognitive clustering in schizophrenia patients, their first-degree relatives and healthy subjects is associated with anterior cingulate cortex volume. Neuroimage Clin. 16, 248\u2013256 (2017).","journal-title":"Neuroimage Clin."},{"key":"1240_CR31","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.psychres.2016.02.042","volume":"238","author":"JQ Wu","year":"2016","unstructured":"Wu, J. Q. et al. Cognitive impairments in first-episode drug-naive and chronic medicated schizophrenia: MATRICS consensus cognitive battery in a Chinese Han population. Psychiatry Res. 238, 196\u2013202 (2016).","journal-title":"Psychiatry Res."},{"key":"1240_CR32","doi-asserted-by":"publisher","first-page":"RC40","DOI":"10.1523\/JNEUROSCI.19-22-j0003.1999","volume":"19","author":"JL Hanover","year":"1999","unstructured":"Hanover, J. L., Huang, Z. J., Tonegawa, S. & Stryker, M. P. Brain-derived neurotrophic factor overexpression induces precocious critical period in mouse visual cortex. J. Neurosci. 19, RC40 (1999).","journal-title":"J. Neurosci."},{"key":"1240_CR33","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S0092-8674(00)81509-3","volume":"98","author":"ZJ Huang","year":"1999","unstructured":"Huang, Z. J. et al. BDNF regulates the maturation of inhibition and the critical period of plasticity in mouse visual cortex. Cell 98, 739\u2013755 (1999).","journal-title":"Cell"},{"key":"1240_CR34","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0896-6273(01)00443-3","volume":"32","author":"SL Patterson","year":"2001","unstructured":"Patterson, S. L. et al. Some forms of cAMP-mediated long-lasting potentiation are associated with release of BDNF and nuclear translocation of phospho-MAP kinase. Neuron 32, 123\u2013140 (2001).","journal-title":"Neuron"},{"key":"1240_CR35","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S0896-6273(00)80853-3","volume":"24","author":"L Minichiello","year":"1999","unstructured":"Minichiello, L. et al. Essential role for TrkB receptors in hippocampus-mediated learning. Neuron 24, 401\u2013414 (1999).","journal-title":"Neuron"},{"key":"1240_CR36","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/hipo.10035","volume":"12","author":"M Alonso","year":"2002","unstructured":"Alonso, M. et al. BDNF-triggered events in the rat hippocampus are required for both short- and long-term memory formation. Hippocampus 12, 551\u2013560 (2002).","journal-title":"Hippocampus"},{"key":"1240_CR37","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1046\/j.1460-9568.2001.01633.x","volume":"14","author":"BK Lipska","year":"2001","unstructured":"Lipska, B. K., Khaing, Z. Z., Weickert, C. S. & Weinberger, D. R. BDNF mRNA expression in rat hippocampus and prefrontal cortex: effects of neonatal ventral hippocampal damage and antipsychotic drugs. Eur. J. Neurosci. 14, 135\u2013144 (2001).","journal-title":"Eur. J. Neurosci."},{"key":"1240_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4137\/CPath.S12530","volume":"6","author":"R Banerjee","year":"2013","unstructured":"Banerjee, R., Ghosh, A. K., Ghosh, B., Bhattacharyya, S. & Mondal, A. C. Decreased mRNA and protein expression of BDNF, NGF, and their receptors in the hippocampus from suicide: an analysis in human postmortem brain. Clin. Med. Insights Pathol. 6, 1\u201311 (2013).","journal-title":"Clin. Med. Insights Pathol."},{"key":"1240_CR39","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1017\/S1461145710000738","volume":"14","author":"AB Klein","year":"2011","unstructured":"Klein, A. B. et al. Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int. J. Neuropsychopharmacol. 14, 347\u2013353 (2011).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"1240_CR40","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/S0028-3908(98)00141-5","volume":"37","author":"W Pan","year":"1998","unstructured":"Pan, W., Banks, W. A., Fasold, M. B., Bluth, J. & Kastin, A. J. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 37, 1553\u20131561 (1998).","journal-title":"Neuropharmacology"},{"key":"1240_CR41","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1017\/S1461145709991015","volume":"13","author":"A Pillai","year":"2010","unstructured":"Pillai, A. et al. Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology. Int. J. Neuropsychopharmacol. 13, 535\u2013539 (2010).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"1240_CR42","doi-asserted-by":"publisher","first-page":"4443","DOI":"10.1007\/s00018-014-1628-x","volume":"71","author":"K Varendi","year":"2014","unstructured":"Varendi, K., Kumar, A., Harma, M. A. & Andressoo, J. O. miR-1, miR-10b, miR-155, and miR-191 are novel regulators of BDNF. Cell. Mol. Life Sci. 71, 4443\u20134456 (2014).","journal-title":"Cell. Mol. Life Sci."}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01240-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01240-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01240-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T15:25:48Z","timestamp":1669821948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-021-01240-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,8]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["1240"],"URL":"https:\/\/doi.org\/10.1038\/s41398-021-01240-x","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,8]]},"assertion":[{"value":"1 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.E.H. has received or plans to receive research funding or consulting fees on research projects from Mitsubishi, Your Energy Systems LLC, Neuralstem, Taisho, Heptares, Pfizer, Luye Pharma, Sound Pharma, Takeda, and Regeneron. None was involved in the design, analysis, or outcomes of the study. All other authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"117"}}